Development and validation of glycolysis-related prognostic score for prediction of prognosis and chemosensitivity of pancreatic ductal adenocarcinoma
© 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd..
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with aggressive biological behaviour. Its rapid proliferation and tumour growth require reprogramming of glucose metabolism or the Warburg effect. However, the association between glycolysis-related genes with clinical features and prognosis of PDAC is still unknown. Here, we used the meta-analysis to correlate the hazard ratios (HR) of 106 glycolysis genes from MSigDB by the cox proportional hazards regression analysis in 6 clinical data sets of PDAC patients to form a training cohort, and a single group of PDAC patients from the TCGA, ICGC, Arrayexpress and GEO databases to form the validation cohort. Then, a glycolysis-related prognosis (GRP) score based on 29 glycolysis prognostic genes was established in 757 PDAC patients from the training composite cohort and validated in 267 ICGC-CA validation cohort (all P < .05). In addition, including PADC, the prognostic value was also confirmed in other 7 out of 30 pan-cancer cohorts. The GRP score was significantly related to specific metabolism pathways, immune genes and immune cells in the patients with PADC (all P < .05). Finally, by combining with immune cells, the GRP score also well-predicted the chemosensitivity of patients with PADC in the TCGA cohort (AUC = 0.709). In conclusion, this study developed a GRP score for patients with PDAC in predicting prognosis and chemosensitivity for PDAC.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
---|---|
Enthalten in: |
Journal of cellular and molecular medicine - 25(2021), 12 vom: 02. Juni, Seite 5615-5627 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Zhang, Xiu-Ping [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antineoplastic Agents |
---|
Anmerkungen: |
Date Completed 01.10.2021 Date Revised 11.11.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1111/jcmm.16573 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM324954980 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM324954980 | ||
003 | DE-627 | ||
005 | 20231225191420.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1111/jcmm.16573 |2 doi | |
028 | 5 | 2 | |a pubmed24n1083.xml |
035 | |a (DE-627)NLM324954980 | ||
035 | |a (NLM)33942483 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Zhang, Xiu-Ping |e verfasserin |4 aut | |
245 | 1 | 0 | |a Development and validation of glycolysis-related prognostic score for prediction of prognosis and chemosensitivity of pancreatic ductal adenocarcinoma |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 01.10.2021 | ||
500 | |a Date Revised 11.11.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. | ||
520 | |a Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with aggressive biological behaviour. Its rapid proliferation and tumour growth require reprogramming of glucose metabolism or the Warburg effect. However, the association between glycolysis-related genes with clinical features and prognosis of PDAC is still unknown. Here, we used the meta-analysis to correlate the hazard ratios (HR) of 106 glycolysis genes from MSigDB by the cox proportional hazards regression analysis in 6 clinical data sets of PDAC patients to form a training cohort, and a single group of PDAC patients from the TCGA, ICGC, Arrayexpress and GEO databases to form the validation cohort. Then, a glycolysis-related prognosis (GRP) score based on 29 glycolysis prognostic genes was established in 757 PDAC patients from the training composite cohort and validated in 267 ICGC-CA validation cohort (all P < .05). In addition, including PADC, the prognostic value was also confirmed in other 7 out of 30 pan-cancer cohorts. The GRP score was significantly related to specific metabolism pathways, immune genes and immune cells in the patients with PADC (all P < .05). Finally, by combining with immune cells, the GRP score also well-predicted the chemosensitivity of patients with PADC in the TCGA cohort (AUC = 0.709). In conclusion, this study developed a GRP score for patients with PDAC in predicting prognosis and chemosensitivity for PDAC | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Validation Study | |
650 | 4 | |a chemosensitivity | |
650 | 4 | |a glycolysis | |
650 | 4 | |a pancreatic ductal adenocarcinoma | |
650 | 4 | |a prognosis | |
650 | 4 | |a score | |
650 | 7 | |a Antineoplastic Agents |2 NLM | |
650 | 7 | |a Biomarkers, Tumor |2 NLM | |
700 | 1 | |a Chen, Qinjunjie |e verfasserin |4 aut | |
700 | 1 | |a Liu, Qu |e verfasserin |4 aut | |
700 | 1 | |a Wang, Yang |e verfasserin |4 aut | |
700 | 1 | |a Wang, Fei |e verfasserin |4 aut | |
700 | 1 | |a Zhao, Zhi-Ming |e verfasserin |4 aut | |
700 | 1 | |a Zhao, Guo-Dong |e verfasserin |4 aut | |
700 | 1 | |a Lau, Wan Yee |e verfasserin |4 aut | |
700 | 1 | |a Gao, Yu-Zhen |e verfasserin |4 aut | |
700 | 1 | |a Liu, Rong |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of cellular and molecular medicine |d 2000 |g 25(2021), 12 vom: 02. Juni, Seite 5615-5627 |w (DE-627)NLM118801236 |x 1582-4934 |7 nnns |
773 | 1 | 8 | |g volume:25 |g year:2021 |g number:12 |g day:02 |g month:06 |g pages:5615-5627 |
856 | 4 | 0 | |u http://dx.doi.org/10.1111/jcmm.16573 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 25 |j 2021 |e 12 |b 02 |c 06 |h 5615-5627 |